Contribution of blood vessels to retinal nerve fiber layer thickness in NMOSD by Oertel, F.C. et al.
Clinical/Scientific
Notes
Frederike C. Oertel*
Hanna Zimmermann,
MEng*
Janine Mikolajczak, MSc
Maria Weinhold, BSc
Ella Maria Kadas, PhD
Timm Oberwahrenbrock,
PhD
Florence Pache, MD
Judith Bellmann-Strobl,
MD
Klemens Ruprecht, MD
Friedemann Paul, MD
Alexander U. Brandt, MD
Neurol Neuroimmunol
Neuroinflamm
2017;4:e338; doi: 10.1212/
NXI.0000000000000338
CONTRIBUTION OF BLOOD VESSELS TO
RETINAL NERVE FIBER LAYER THICKNESS IN
NMOSD
Neuromyelitis optica spectrum disorders (NMOSDs)
are relapsing inflammatory demyelinating disorders with
optic neuritis (ON) as the hallmark. ON causes neuro-
axonal damage to the optic nerve and retina, regularly
leading to severely impaired visual acuity (VA).1
Peripapillary retinal nerve fiber layer (pRNFL)
thickness measured by optical coherence tomography
(OCT) has been increasingly recognized as a marker
for neuroaxonal damage and correlate of visual dys-
function.1 As such, pRNFL is implemented as an
outcome in clinical trials of ON-associated disorders.
Blood vessels (BVs) running within the pRNFL con-
tribute approximately 13% to an average RNFL
thickness2 and could present an important con-
founder when tracking small pRNFL changes or in
diseases with severe thinning such as NMOSD.1
Against this background, the objective of this study
was to investigate the influence of retinal BVs on
pRNFL measurements in an NMOSD cohort.
Methods. Forty patients from a prospective observa-
tional cohort study at the NCRC at Charité–
Universitätsmedizin Berlin were enrolled (women/
men: 39/1, age: 44.7 6 15.4 years, 42 ON eyes).
Inclusion criteria were a minimum age of 18 years
and diagnosis of NMOSD according to the 2015
IPND criteria3 (n 5 37, aquaporin-4 antibody sero-
positive n 5 28) or myelin oligodendrocyte glyco-
protein-IgG–associated encephalomyelitis (n 5 3).4
Exclusion criteria were any other diseases which could
influence OCT results.
All patients were examined with a Spectralis
SD-OCT (Heidelberg Engineering, Heidelberg,
Germany) using automatic real time (ART) function
for image averaging. pRNFL was measured with
a 3.4 mm ring scan around the optic nerve head
(12°, 1536 A scans 16 # ART # 100) and seg-
mented semiautomatically (Eye Explorer 1.9.10.0
with viewing module 6.0.9.0) and manually cor-
rected by an experienced grader. BV positions were
automatically detected by OCTSEG5 (figure, A and
B) and manually corrected. Three eyes were
excluded because of insufficient image quality based
on OSCAR-IB criteria.
High-contrast VA was examined monocularly
under habitual correction and photopic conditions
with ETDRS charts at a simulated 20 ft distance
using the Optec 6500 P System (Stereo Optical,
Chicago, IL).
pRNFL without vessels was calculated as mean
thickness of all ring scan positions not marked as part
of vessels and was compared with pRNFL with vessels
using paired t tests. We performed Pearson correla-
tion analyses for evaluation of the relationship
between pRNFL and VA and Fisher z test for corre-
lation comparison. The relative BV contribution in
percentage was calculated as ([pRNFLwith vessels 2
pRNFLwithout vessels]/pRNFLwith vessels 3 100%). All
statistical tests were performed using R 3.1 with sig-
nificance established at p , 0.05. The study was
approved by the local Ethics Committee at
Charité–Universitätsmedizin Berlin and was con-
ducted in accordance with the Declaration of
Helsinki.
Results. pRNFL measurements were thinner with-
out including BVs (76.1 6 26.6 mm with, 68.3 6
26.2 mm without, p, 2e216; figure, C). Relative BV
contribution increased with lower pRNFL (r 5
20.700, p 5 1e212) (figure, D). When only consid-
ering eyes with pRNFL thickness below 60 mm, the
mean relative BV contribution was significantly
higher with 16% 6 5% compared with 9% 6 3%
in eyes with RNFL .60 mm (p 5 8e28).
VA (36 6 19 ETDRS letters) was associated with
pRNFL including BV (r 5 0.621, p 5 2e29) and
without BV (r 5 0.618, p 5 2e29). In eyes with
pRNFL measurements below 60 mm, pRNFL-VA
correlation was numerically higher for pRNFL
excluding BV (r 5 0.495, p 5 0.007) than pRNFL
including BV (r 5 0.482, p 5 0.009), but the dif-
ference was not significant (p 5 0.476). There were
no influences of antibody status, disease duration and
therapy on pRNFL, relative BV contribution, or
enlargement of BV areas with pRNFL thinning (data
not shown).6
Discussion. BV contribution to average pRNFL
measurements is higher in thin compared with
normal/high pRNFL measurements.
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A previous study reported an average BV contribu-
tion of 13% to pRNFL measurements.2 Our study
expands these findings by showing that BV contribu-
tion is increased in low pRNFL measurements like
the ones regularly found in NMOSD patients with
severe ON.
A relevant contribution of BV artifacts to measure-
ment noise has been reported.7 Although our results
did not show a structure-function correlation
improvement for vessel-corrected measurements, they
suggest a downgrade in pRNFL measurement sensi-
tivity. In NMOSD cohorts, a wide range of pRNFL
thickness measurements are seen, including those
lower than 60 mm.1 Typically, pRNFL differences
of only a few micrometers are used to evaluate drug
efficacy in ON trials.8 Thus, in longitudinal studies,
vessel artifacts potentially interfere with the compara-
bility of an absolute thickness change because the
relative vessel contribution increases with thinner
pRNFL.
We propose analyzing OCT data in studies
including NMOSD and other conditions with low
pRNFL measurements in addition to vessel correc-
tion. Further studies of retrospective and prospective
data and larger cohorts are required to confirm and
specify BV influence and to identify reliable surro-
gates for tracking ON-related damage in NMOSD.
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Figure Contribution of blood vessels to retinal nerve fiber layer thickness
(A) pRNFL scanned by optical coherence tomography, segmented with vessel detection. (B)
Mean pRNFL thickness in mm; all regions including vessels and only regions without vessels.
(C) Correlation of the relative blood vessel contribution to the pRNFL including vessels.
pRNFL 5 peripapillary retinal nerve fiber layer.
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